Intellia pauses two late-stage CRISPR gene-editing trials after emergence of safety concern - statnews.com

Intellia Therapeutics said Monday it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.  The companys stock plummeted more than 35%…